Myasthenia gravis trials in Poland

In Poland 22 Also abroad 123

22 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients with Myasthenia Gravis
Where
Cracow, Katowice, Lodz, Lublin, Warsaw
Age
18 years and over
People
59 worldwide
Run by
NMD Pharma A/S
See details and how to join2023-507539-40-00 · EU 2023-507539-40-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Where
Cracow, Katowice, Lublin, Poznan, Warsaw, Zabrze
Age
18 years and over
People
120 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT07463521 · EU 2025-524756-54-00
Phase 3Taking people
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Where
Cracow, Katowice, Lublin, Poznan, Warsaw, Zabrze
Age
18 years and over
People
100 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT07465289 · EU 2025-524757-14-00
Phase 3Taking people
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Where
Bydgoszcz, Cracow, Katowice, Lublin, Warsaw
Age
18 years and over
People
199 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT04951622 · EU 2023-504152-97-00
Phase 2/3Taking people
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
Where
Katowice, Warsaw
Age
12 years to 17 years
People
8 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT06055959 · EU 2022-502072-23-00
Phase 2/3Taking people
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Where
Gdansk
Age
2 years to 17 years
People
12 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05265273 · EU 2022-502539-21-00
Phase 2Taking people
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
Where
Bydgoszcz, Cracow, Katowice, Lublin, Poznan, Warsaw
Age
18 years and over
People
40 worldwide
Run by
argenx
See details and how to joinNCT07673627 · EU 2025-522939-33-00
Phase 2/3Enrolling by invitation
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
Where
Gdansk, Katowice, Warsaw
Age
2 years to 18 years
People
12 worldwide
Run by
argenx
See details and how to joinNCT05374590 · EU 2023-507379-23-00
Phase 3Taking people
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
Where
Bydgoszcz, Cracow, Katowice, Lublin, Poznan, Skorzewo, Warsaw, Wroclaw
Age
18 years to 80 years
People
195 worldwide
Run by
Dianthus Therapeutics
See details and how to joinNCT07647510 · EU 2026-525298-38-00
Phase 2Taking people
A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
Where
Cracow, Katowice, Kielce, Lodz, Lublin, Poznan, Zabrze, Zory
Age
18 years and over
People
120 worldwide
Run by
TG Therapeutics, Inc.
See details and how to joinNCT07673744 · EU 2025-524630-26-00
No phaseTaking people
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Where
Bydgoszcz, Katowice, Krakow, Warsaw
Age
18 years and over
People
70 worldwide
Run by
argenx
See details and how to joinNCT07294170
Phase 2Taking people
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Where
Bydgoszcz, Katowice
Age
2 years to 17 years
People
15 worldwide
Run by
Amgen
See details and how to joinNCT06987539 · EU 2025-520993-20-00
Phase 3Taking people
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Where
Cracow, Gdansk, Warsaw, Zabrze
Age
18 years and over
People
264 worldwide
Run by
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
See details and how to joinNCT06463587 · EU 2023-507746-83-00
Phase 1/2Taking people
A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients with Generalized Myasthenia Gravis
Where
Bydgoszcz, Cracow, Katowice, Lublin, Poznań, Skorzewo, Warsaw, Zabrze
Age
18 years and over
People
38 worldwide
Run by
Aurinia Pharmaceuticals Inc.
See details and how to join2025-525127-27-00 · EU 2025-525127-27-00
Phase 3Enrolling by invitation
An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
Where
Katowice, Warsaw
Age
12 years to 17 years
People
8 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT06435312 · EU 2022-502073-42-00
Phase 2/3Taking people
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
Where
Gdansk, Katowice, Warsaw
Age
2 years to 17 years
People
12 worldwide
Run by
argenx
See details and how to joinNCT06392386 · EU 2023-506159-12-00
Phase 2Taking people
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Where
Bydgoszcz, Cracow, Katowice, Warsaw
Age
18 years and over
People
70 worldwide
Run by
argenx
See details and how to joinNCT07284420 · EU 2025-522492-28-00
No phaseTaking people
Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis
Where
Bydgoszcz, Gdansk, Katowice, Krakow, L DZ, Lublin, Poznan, Szczecin, Warsaw, Wroclaw
Age
18 years and over
People
50
Run by
AstraZeneca
See details and how to joinNCT06909253
Phase 2Taking people
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
Where
Katowice, Krakow, Lublin, Myślenice, Warsaw
Age
18 years and over
People
84 worldwide
Run by
NMD Pharma A/S
See details and how to joinNCT06414954
Phase 3Taking people
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Where
Cracow, Gdansk, Katowice, Lublin, Warsaw
Age
18 years to 80 years
People
231 worldwide
Run by
Immunovant Sciences GmbH
See details and how to joinNCT07039916 · EU 2024-515979-35-00
Phase 3Taking people
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Where
Warsaw
Age
6 years to 17 years
People
12 worldwide
Run by
Alexion Pharmaceuticals, Inc.
See details and how to joinNCT06607627 · EU 2024-515157-17-00
Phase 1/2Taking people
A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
Where
Katowice, Nowa Sol, Poznan
Age
18 years to 74 years
People
96 worldwide
Run by
ImmunAbs Inc.
See details and how to joinNCT07250750 · EU 2025-522406-20-00